Fig 1.
CONSORT flow diagram of included subjects.
bOPV = bivalent Oral Polio Vaccine; IPV = Inactivated Polio Vaccine; ELISPOT = Enzyme-Linked ImmunoSpot.
Table 1.
Median mucosal α4β7+ and total IgA and IgG ASCs at day 7 by intervention group and poliovirus serotype.
Fig 2.
a: Proportion of subjects with α4β7+ ASC IgA and/or IgG response by intervention group and poliovirus serotype. b: Proportion of subjects with total ASC IgA and/or IgG response by intervention group and poliovirus serotype.
Fig 3.
a: Proportion of subjects excreting virus after booster vaccination with OPV and IPV vaccines by intervention group and poliovirus serotype. PV1: Poliovirus type 1; PV2: Poliovirus type 2; PV3: Poliovirus type 3; IPV: Inactivated Polio Vaccine; bOPV = bivalent Oral Polio Vaccine. b: Proportion of subjects with immune response after booster vaccination with OPV and IPV vaccines by intervention group and poliovirus serotype.
Table 2.
Median mucosal α4β7+ ASCs at day 7 and proportion of subjects with mucosal α4β7+ IgA and/or IgG ASC response by excretion status of poliovirus serotypes 1 and 3.
Table 3.
Sensitivity, specificity, positive and negative predictive values of mucosal α4β7+IgA- and/or IgG- ASC responses.
Table 4.
Proportion of subjects with IgA- and/or IgG-ASC responses to poliovirus types 1, 2 and 3 and systemic immune response (seroconversion or 4-fold rise in neutralizing antibody titers).